Vitamin K is not a single compound. It is a family of fat-soluble vitamins sharing a common naphthoquinone chemical structure but differing profoundly in their biological functions. Vitamin K1 (phylloquinone), found primarily in leafy green vegetables, is absorbed in the liver and used almost exclusively for hepatic clotting factor synthesis — it is the K that doctors monitor in patients on warfarin. Vitamin K2 (menaquinones), found in fermented foods and animal products, reaches extrahepatic tissues — arterial walls, bone, kidneys, and the brain — where it activates a distinct set of vitamin K-dependent proteins with no role in blood clotting.
The most consequential of these K2-dependent proteins is Matrix Gla Protein (MGP), which is the most potent known inhibitor of vascular and soft tissue calcification. MGP is expressed in arterial smooth muscle cells and must be carboxylated by vitamin K2 to become active. Without adequate K2, MGP remains in an uncarboxylated, non-functional form (ucMGP) — and arterial calcification proceeds unchecked. This mechanism explains both the observational data linking K2 intake to cardiovascular health and the physiological rationale for pairing vitamin D3 (which increases calcium absorption) with K2 (which directs that calcium to bone rather than arterial walls).
Rotterdam Study (Geleijnse 2004): The landmark epidemiological study. N=4,807 adults, 10-year follow-up, dietary K1 and K2 assessment. The K2-cardiovascular association was driven by MK-4 and MK-7 from cheese and other fermented foods. No association with K1. The 57% CHD mortality reduction in the highest K2 tertile is striking for a nutrient with no known toxicity at supplemental doses.
Knapen 2015 (Osteoporosis International, N=244): 3-year RCT, postmenopausal women, MK-7 180mcg/day vs placebo. Primary outcomes: arterial stiffness and bone mineral density. Results: pulse wave velocity (marker of arterial stiffness) decreased significantly in the K2 group vs placebo (-0.29 m/s at 3 years). Bone mineral density of the lumbar spine and femoral neck was significantly preserved. This is one of the only RCTs to show direct arterial stiffness improvement from a supplement.
dp-ucMGP as a biomarker: Dephospho-uncarboxylated MGP (dp-ucMGP) is an emerging clinical biomarker of K2 status. High dp-ucMGP = insufficient K2 to carboxylate available MGP = active arterial calcification risk. Multiple cohort studies show high dp-ucMGP predicts cardiovascular events and all-cause mortality independently of traditional risk factors. Supplementation with MK-7 lowers dp-ucMGP — direct evidence of biological activity. This biomarker can be ordered through specialty labs.
Vitamin K2 and warfarin: The pharmacological concern about K2 interfering with warfarin anticoagulation is based on K1 — the liver uses K1 for clotting factor synthesis, and K1 competes with warfarin at VKOR (vitamin K epoxide reductase). Vitamin K2 at physiological doses (90–200mcg MK-7) has minimal effect on warfarin INR in most patients because the enzyme affinity and tissue distribution differ. However, because MK-7's long half-life can accumulate at higher doses and because individual responses vary, patients on warfarin should consult their anticoagulation provider before adding MK-7 supplementation and have INR monitored more frequently initially.
Form: MK-7 (menaquinone-7) — preferred over MK-4 for supplementation due to 3-day half-life enabling once-daily dosing and superior bioavailability per microgram; MK-7 is derived from natto fermentation (Bacillus subtilis natto); ensure the supplement specifies MK-7, not generic "vitamin K2" which may be primarily MK-4.
Dose: 90–180mcg MK-7 once daily; 90mcg is the dose studied in the Knapen trial and widely used; 180mcg is the dose some practitioners prefer for more rapid dp-ucMGP lowering; no established upper tolerable limit (no toxicity reported at supplemental doses); take with a fat-containing meal for optimal absorption (fat-soluble vitamin).
Pairing with D3: If taking vitamin D3 at doses ≥2,000 IU/day, co-administration of K2 MK-7 is mechanistically rational to ensure MGP activation keeps pace with increased calcium absorption; standard D3+K2 combination: D3 2,000–5,000 IU + K2 MK-7 100–200mcg once daily with food; many commercial products combine both in one capsule at these ratios.
Dietary sources to maximize alongside supplementation: Regular consumption of hard aged cheeses (Gouda, aged Cheddar, Jarlsberg) provides meaningful MK-4; grass-fed butter provides more K2 than conventional; egg yolks from pastured chickens; if natto is accessible and palatable, 30g (1 tbsp) of natto provides 280mcg MK-7 — more than any supplement dose studied.
As an Amazon Associate, StackProtocol earns from qualifying purchases made through links on this page. This does not affect the price you pay.